Isis Pharmaceuticals (ISIS) 24.51 $ISIS
Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO(R)
Business Wire - Thu May 08, 8:01AM CDT
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO(R) (mipomersen sodium) injection. KYNAMRO, selected for being a very important orphan therapy to reach the market in the United States, is an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo
, total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 11:20 a.m. PT in Las Vegas, NV.
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
Atrial Fibrillation - Pipeline Review, H1 2014
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx455/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ARCA biopharma, Inc. - Armetheon, Inc. - Cardiome Pharma Corp - Daiichi Sankyo Company, Limited - Gilead Sciences, Inc. - HUYA Bioscience International, LLC - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Milestone Pharmaceuticals, Inc. - Nissan Chemical Industries, Ltd. - Nyken BV - Otsuka Holdings Co., Ltd. - Serodus ASA - Xention Limited Drug Profiles: - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - colchicine - bucindolol hydrochloride - vernakalant hydrochloride - budiodarone - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - onabotulinumtoxinA - XEN-D0101 - OPC-108459 - IKACh - XEN-D0104 - HBI-3000 - MSP-2017 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - SER-120 - budiodarone - Drug For Atrial Fibrillation - Adenosine A1 Agonist for Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/zrx455/atrial
Aegerion Pharmaceuticals Tumbles After a Big Earnings Miss
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 11:04AM CDT
Shares of Aegerion Pharmaceuticals are down nearly 27% as of this writing after the company reported lackluster first-quarter earnings and lowered its full-year guidance last night. Aegerion reported net...
Shares of ISIS Down 53.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 07, 10:59AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 2 months, Isis Pharmaceuticals has returned 53.94% as of today's recent price of $23.05.
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
Upgrade Alert for Isis Pharmaceuticals (ISIS)
Comtex SmarTrend(R) - Wed May 07, 6:57AM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $24.66 on volume of 3.5 million shares, above average daily volume of 2.5 million. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
Lower Milestone Revenue Widens Isis Pharmaceuticals' Q1 Loss
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 11:45AM CDT
Collaborative antisense drug developer Isis Pharmaceuticals touted the maturation of its pipeline during its first-quarter earnings results today, but it couldn't hide the fact that both its top and bottom lines reversed course from the...
Isis Reports Financial Results and Highlights for First Quarter 2014
PR Newswire - Tue May 06, 7:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013. Isis' first quarter 2014 pro forma NOL was higher than the same period last year primarily due to variations in the timing of milestone payments from its partners and the planned increase in operating expenses associated with the Company's late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $29.7 million for the three months ended March 31, 2014 compared to income from operations of $1.6 million for the same period in 2013. Isis maintained its strong cash position and ended the first quarter of 2014 with approximately $631 million in cash compared to $657 million at December 31, 2013.
Earnings Releases, Pricing Updates, and Stock Price Movements - Analyst Notes on Valero, Praxair, Total SA, Isis Pharmaceuticals and Cigna
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Valero Energy Corporation (NYSE: VLO), Praxair Inc. (NYSE: PX), Total SA (NYSE: TOT), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2050-100free.
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia
PR Newswire - Fri May 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. In this open-label study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all three patients achieving a triglyceride level below 500 mg/dL, which substantially reduces the risk of an acute pancreatitis event. In addition, significant reductions in chylomicrons were observed that correlated with reductions in triglyceride levels. These data were presented today by Dr. Daniel Gaudet at the National Lipid Association clinical lipid update meeting in Orlando, Florida.
Isis Pharmaceuticals to Present at the Deutsche Bank 39th Annual Health Care Conference
PR Newswire - Thu May 01, 3:01PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 12:50 p.m. ET in Boston, MA.
Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
PR Newswire - Thu May 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes. In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant average mean percent reduction from baseline of 88 percent (p=0.02) in apolipoprotein C-III (apoC-III) and 69 percent (p=0.02) in triglycerides, and an average mean percent increase of 42 percent (p=0.03) in high-density lipoprotein cholesterol (HDL-C) after 13 weeks of dosing. All treated patients achieved triglyceride levels of less than 104 mg/dL and averaged triglyceride levels under 76 mg/dL by four weeks, and the average triglyceride level was maintained under 76 mg/dL until the end of treatment (a normal triglyceride level is <150 mg/dL). In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant reductions in measures of glucose control. The absolute mean reductions in hemoglobin A1c (HbA1c) were 1.22 percent (placebo-adjusted) and 0.44 percent (from baseline) (p=0.03) after 25 weeks. In addition to the statistically significant reductions in HbA1c, patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions in serum fructosamine of 39 mol/L (p=0.05) and in glycated albumin of 2 percent (p=0.03) (from baseline) after 13 weeks of dosing. The effects of ISIS-APOCIIIRx observed on measures of glucose control were in addition to those achieved with each patient's existing therapeutic regimen of metformin. Improvements in indicators of insulin sensitivity were also observed in patients suggesting that inhibition of apoC-III could improve insulin sensitivity in patients with high triglycerides and type 2 diabetes.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Isis Pharmaceuticals Down 46.1% Since SmarTrend Downtrend Call (ISIS)
Comtex SmarTrend(R) - Wed Apr 30, 9:37AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 2 months, Isis Pharmaceuticals has returned 46.11% as of today's recent price of $26.97.
Webcast Alert: Isis Pharmaceuticals' First Quarter 2014 Financial Results Conference Call
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the strategic alliance between Isis and Biogen Idec (NASDAQ:BIIB) has been honored with the Alliance 2014 Breakthrough Award. The award, sponsored by Thomson Reuters Recap, was presented at the Allicense 2014 Conference in San Francisco on April 29, 2014.
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 6.85% Yesterday
Comtex SmarTrend(R) - Tue Apr 29, 5:16PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $29.04 to a high of $33.24. Yesterday, the shares fell 6.8%, which took the trading range below the 3-day low of $29.50 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO(R)
Business Wire - Thu May 08, 8:01AM CDT
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO(R) (mipomersen sodium) injection. KYNAMRO, selected for being a very important orphan therapy to reach the market in the United States, is an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo
, total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 11:20 a.m. PT in Las Vegas, NV.
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
Atrial Fibrillation - Pipeline Review, H1 2014
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx455/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ARCA biopharma, Inc. - Armetheon, Inc. - Cardiome Pharma Corp - Daiichi Sankyo Company, Limited - Gilead Sciences, Inc. - HUYA Bioscience International, LLC - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Milestone Pharmaceuticals, Inc. - Nissan Chemical Industries, Ltd. - Nyken BV - Otsuka Holdings Co., Ltd. - Serodus ASA - Xention Limited Drug Profiles: - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - colchicine - bucindolol hydrochloride - vernakalant hydrochloride - budiodarone - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - onabotulinumtoxinA - XEN-D0101 - OPC-108459 - IKACh - XEN-D0104 - HBI-3000 - MSP-2017 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - SER-120 - budiodarone - Drug For Atrial Fibrillation - Adenosine A1 Agonist for Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/zrx455/atrial
Aegerion Pharmaceuticals Tumbles After a Big Earnings Miss
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 11:04AM CDT
Shares of Aegerion Pharmaceuticals are down nearly 27% as of this writing after the company reported lackluster first-quarter earnings and lowered its full-year guidance last night. Aegerion reported net...
Shares of ISIS Down 53.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 07, 10:59AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 2 months, Isis Pharmaceuticals has returned 53.94% as of today's recent price of $23.05.
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
Upgrade Alert for Isis Pharmaceuticals (ISIS)
Comtex SmarTrend(R) - Wed May 07, 6:57AM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $24.66 on volume of 3.5 million shares, above average daily volume of 2.5 million. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
Lower Milestone Revenue Widens Isis Pharmaceuticals' Q1 Loss
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 11:45AM CDT
Collaborative antisense drug developer Isis Pharmaceuticals touted the maturation of its pipeline during its first-quarter earnings results today, but it couldn't hide the fact that both its top and bottom lines reversed course from the...
Isis Reports Financial Results and Highlights for First Quarter 2014
PR Newswire - Tue May 06, 7:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013. Isis' first quarter 2014 pro forma NOL was higher than the same period last year primarily due to variations in the timing of milestone payments from its partners and the planned increase in operating expenses associated with the Company's late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $29.7 million for the three months ended March 31, 2014 compared to income from operations of $1.6 million for the same period in 2013. Isis maintained its strong cash position and ended the first quarter of 2014 with approximately $631 million in cash compared to $657 million at December 31, 2013.
Earnings Releases, Pricing Updates, and Stock Price Movements - Analyst Notes on Valero, Praxair, Total SA, Isis Pharmaceuticals and Cigna
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Valero Energy Corporation (NYSE: VLO), Praxair Inc. (NYSE: PX), Total SA (NYSE: TOT), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2050-100free.
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia
PR Newswire - Fri May 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. In this open-label study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all three patients achieving a triglyceride level below 500 mg/dL, which substantially reduces the risk of an acute pancreatitis event. In addition, significant reductions in chylomicrons were observed that correlated with reductions in triglyceride levels. These data were presented today by Dr. Daniel Gaudet at the National Lipid Association clinical lipid update meeting in Orlando, Florida.
Isis Pharmaceuticals to Present at the Deutsche Bank 39th Annual Health Care Conference
PR Newswire - Thu May 01, 3:01PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 12:50 p.m. ET in Boston, MA.
Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
PR Newswire - Thu May 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes. In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant average mean percent reduction from baseline of 88 percent (p=0.02) in apolipoprotein C-III (apoC-III) and 69 percent (p=0.02) in triglycerides, and an average mean percent increase of 42 percent (p=0.03) in high-density lipoprotein cholesterol (HDL-C) after 13 weeks of dosing. All treated patients achieved triglyceride levels of less than 104 mg/dL and averaged triglyceride levels under 76 mg/dL by four weeks, and the average triglyceride level was maintained under 76 mg/dL until the end of treatment (a normal triglyceride level is <150 mg/dL). In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant reductions in measures of glucose control. The absolute mean reductions in hemoglobin A1c (HbA1c) were 1.22 percent (placebo-adjusted) and 0.44 percent (from baseline) (p=0.03) after 25 weeks. In addition to the statistically significant reductions in HbA1c, patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions in serum fructosamine of 39 mol/L (p=0.05) and in glycated albumin of 2 percent (p=0.03) (from baseline) after 13 weeks of dosing. The effects of ISIS-APOCIIIRx observed on measures of glucose control were in addition to those achieved with each patient's existing therapeutic regimen of metformin. Improvements in indicators of insulin sensitivity were also observed in patients suggesting that inhibition of apoC-III could improve insulin sensitivity in patients with high triglycerides and type 2 diabetes.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Isis Pharmaceuticals Down 46.1% Since SmarTrend Downtrend Call (ISIS)
Comtex SmarTrend(R) - Wed Apr 30, 9:37AM CDT
SmarTrend identified a Downtrend for Isis Pharmaceuticals (NASDAQ:ISIS) on March 10th, 2014 at $50.05. In approximately 2 months, Isis Pharmaceuticals has returned 46.11% as of today's recent price of $26.97.
Webcast Alert: Isis Pharmaceuticals' First Quarter 2014 Financial Results Conference Call
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the strategic alliance between Isis and Biogen Idec (NASDAQ:BIIB) has been honored with the Alliance 2014 Breakthrough Award. The award, sponsored by Thomson Reuters Recap, was presented at the Allicense 2014 Conference in San Francisco on April 29, 2014.
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 6.85% Yesterday
Comtex SmarTrend(R) - Tue Apr 29, 5:16PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $29.04 to a high of $33.24. Yesterday, the shares fell 6.8%, which took the trading range below the 3-day low of $29.50 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
